---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-203913"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:59:02.911730+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Damora Therapeutics CFO Lori Firmani to depart May 1; Brian Burkavage appointed principal financial officer

## Summary
- Effective May 1, 2026, Lori Firmani will cease serving as CFO of Damora Therapeutics.
- Firmani receives lump-sum salary continuation, prorated bonus, $6K HSA, and full equity acceleration.
- Brian Burkavage, current SVP Finance, appointed principal financial and accounting officer effective May 1.
- Burkavage previously SVP Finance and CAO at IO Biotech; CPA with 11 years at Ernst & Young.

## SEC filing metadata
- accession: 0001193125-26-203913
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000119312526203913/0001193125-26-203913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000119312526203913/dmra-20260428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-203913
- JSON: https://secwatch.observer/filing/0001193125-26-203913.json
- Plain text: https://secwatch.observer/filing/0001193125-26-203913.txt

## Key facts
- Executive change
  Brian Burkavage was appointed as principal financial officer and principal accounting officer at Damora Therapeutics, Inc..
  - Action: appointed
  - Role: principal financial officer and principal accounting officer
  source text: the Board appointed Brian Burkavage, the Company’s current Senior Vice President, Finance, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Time.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800315/000119312526203913/0001193125-26-203913-index.htm
- Executive change
  Lori Firmani departed as Chief Financial Officer at Damora Therapeutics, Inc..
  - Action: would cease serving
  - Role: Chief Financial Officer
  source text: the Board of Directors (the “Board”) of Damora Therapeutics, Inc. (the “Company”) determined that, effective as of May 1, 2026 (the “Effective Time”), Lori Firmani would cease serving as the Company’s Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800315/000119312526203913/0001193125-26-203913-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.